Latest endocrine therapy Stories
Research published in the July issue of The Journal of Nuclear Medicine shows imaging progesterone receptor (PR) status also may be able to identify responders and nonresponders to endocrine therapy at an early stage.
Researchers from Baylor College of Medicine have been awarded more than $5 million from Susan G. Komen for the Cure for three new breast cancer research grants, including a prestigious Komen Promise Grant.
Aside from all the other health issues obesity can cause, here is another one to add to the list. According to a recent study, obesity is associated with worse outcomes overall in early-stage breast cancer.
Obesity is associated with worse outcomes overall in early-stage breast cancer.
An international research team led by Georgetown Lombardi Comprehensive Cancer Center has found biological differences in hormone-receptor positive breast cancer that are linked to the timing of recurrence despite endocrine therapy.
The first roadmap to mathematical modeling of a powerful basic "decision circuit" in breast cancer has been developed and published in Nature Reviews Cancer.
A new genomic test combining multiple signatures â€“ a patient's estrogen receptor status, endocrine therapy response, chemotherapy resistance and sensitivity â€“ shows promise as a predictor of chemotherapy response and survival benefit in women with invasive breast cancer.
Development of a predictive test that included genomic signatures that indicated chemoresistance, chemosensitivity and endocrine sensitivity for women with newly diagnosed breast cancer identified patients with a high probability of survival following chemotherapy.
Grant awarded to Dr. Jacek Pinski to conduct the study at the Norris Comprehensive Cancer Center of the University of Southern California QUEBEC CITY, Aug. 5 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc.
QUEBEC CITY, July 14 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company"), a late-stage drug development company specialized in oncology and endocrine therapy, today announced that its partner, Keryx Biopharmaceuticals, Inc.